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We characterized human monoclonal antibodies (MAbs) cloned from influenza virus-infected patients and
from influenza vaccine recipients by complement-dependent lysis (CDL) assay. Most MAbs active in CDL were
neutralizing, but not all neutralizing MAbs can mediate CDL. Two of the three stalk-specific neutralizing
MAbs tested were able to mediate CDL and were more cross-reactive to temporally distant H1N1 strains than
the conventional hemagglutination-inhibiting and neutralizing MAbs. One of the stalk-specific MAbs was
subtype cross-reactive to H1 and H2 hemagglutinins, suggesting a role for stalk-specific antibodies in protec-
tion against influenza illness, especially by a novel viral subtype which can cause pandemics.
Human influenza is a highly contagious acute respiratory
illness that is responsible for significant morbidity and excess
mortality, especially in the elderly and the very young world-
wide. Every year in the United States, on average 5% to 20%
of the population acquires influenza, more than 200,000 people
are hospitalized for influenza complications, and influenza-
related deaths range from 3,000 to 49,000. The elderly, young
children, and individuals with certain health conditions are at
high risk for serious influenza complications (Centers for Dis-
ease Control and Prevention [http://www.cdc.gov/flu/about
/disease/index.htm]). Current vaccine approaches depend pri-
marily on the induction of antibodies to the viral surface
protein hemagglutinin (HA). Serum hemagglutination inhibi-
tion (HAI) titers to the circulating virus of 1:40 or greater are
associated with significant protection against influenza illness
(15). In the elderly, however, HAI titers measured pre- and
postvaccination were not distinguishable between subjects who
subsequently developed influenza illness and those who did not
(12), showing the limitation of the HAI titer as an indicator of
protection in this population.
Antibodies inducing HAI and neutralization are generally
considered subtype specific and bind to the globular head re-
gion of the HA, a receptor binding site (14). In 1993, however,
a mouse monoclonal antibody (MAb), C179, which neutralizes
H1, H2, H5, and H9 subtypes, was isolated (13, 18; C179
datasheet [http://catalog.takara-bio.co.jp/en/PDFFiles/M145
_DS_e.pdf]). Recently, four groups reported human MAbs
with similar characteristics which were able to neutralize group
1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, and H16 based on
phylogenetic analysis [17]) influenza A viruses (1, 2, 20). These
stalk region-specific antibodies cannot inhibit hemagglutina-
tion (2, 13, 20, 23). The presence of these MAbs indicates that
at the clonal level, some neutralizing and hemagglutination-
inhibiting antibodies are distinct and their activities are not
correlated.
In addition to the neutralization of cell-free virus by anti-
bodies to HA and the interference of virus release from in-
fected cells by antibodies to neuraminidase (NA), influenza
virus-specific antibodies bind to infected cells and are able to
lyse the virus-infected cells through activation of complement
(complement-dependent lysis [CDL]) (16, 21). The comple-
ment system plays several roles in response to influenza virus
infection. In primary infection with influenza virus, mice defi-
cient in component C3 showed delayed viral clearance and
increased viral titers in lungs (9). The addition of complement
can enhance the neutralization of influenza virus by antibodies
in vitro (5). Complement is also known to enhance influenza
virus-specific CD4 and CD8 T cell responses and to help
maintain long-term memory of influenza viruses in mice (3, 9).
Complement, therefore, can link innate and adaptive immuni-
ties and is probably important to consider for vaccine devel-
opment (4).
In this study, we analyzed 13 HA-specific human MAbs
molecularly cloned from plasmablasts obtained from patients
infected with 2009 pandemic influenza (23) or from recipients
of prepandemic seasonal influenza vaccines (24) by CDL assay,
which is a modification of a method reported previously (16,
21). Cells from the human lung cancer cell line A549 (type II
alveolar epithelial cells) (11) infected with influenza virus were
used as targets instead of mouse kidney or embryo cells. All
MAbs have the same constant region of human IgG1 subclass
(the variable region of an antibody was cloned by reverse
transcription [RT]-PCR and recombined with the constant re-
gion of IgG1), the most abundant subclass which can activate
the classical pathway of the complement system (7, 8). These
MAbs were categorized into four different groups based on
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their microneutralization (MN) and HAI titer patterns against
2009 pandemic [A/California/4/2009 (H1N1)] or seasonal (A/
Solomon Islands/3/2006) H1N1 strains (Table 1).
First we tested these 13 MAbs for CDL activity against
target cells infected with 2009 pandemic or seasonal H1N1
strains at a concentration of 10 g/ml (Table 1). Six MAbs
(1009-3B06, TIV-1, 1009-3B05, 1009-3E06, 70-1F02, and
TIV-2) showed moderate to high levels of specific immune lysis
(16 to 44%) by CDL of seasonal H1N1 influenza virus-infected
target cells, and four MAbs (1009-3B06, 1009-3F01, 1009-
3B05, and 70-1F02) showed moderate levels (14 to 18%) of
CDL activity on 2009 pandemic H1N1 virus-infected target
cells (in CDL assays, approximately 40 to 60% of target cells
were infected with influenza virus; results were confirmed by
fluorescence-activated cell staining [data not shown]). Five
MAbs which showed binding only to whole viruses by enzyme-
linked immunosorbent assay (ELISA; MN/HAI MAbs) did
not have CDL activity at 10 g/ml. Subsequently, the seven
MAbs which mediated CDL at 10 g/ml were tested at lower
concentrations (Fig. 1). These MAbs retained CDL activity at
concentrations as low as 0.04 to 4 g/ml. There were three
MAbs which mediated CDL against both 2009 pandemic
H1N1-infected and seasonal H1N1 virus-infected target cells
(1009-3B06, 1009-3B05, and 70-1F02). For these MAbs, higher
concentrations were needed to mediate CDL against the 2009
pandemic H1N1 virus-infected target cells than for those in-
fected with the seasonal A/Solomon Islands/3/2006 (H1N1)
strain, which is consistent with previous analyses in that MAbs
1009-3B06 and 70-1F02 had higher minimum effective concen-
trations against the 2009 pandemic virus than the seasonal
viruses in MN assays (23). At these minimum effective concen-
trations for MN, both MAbs were also active in CDL assays
(Fig. 1). MAb TIV-1, specific to seasonal H1N1, was active
only in a CDL assay against seasonal H1N1 strain-infected
target cells.
MN and CDL antibody assay results, however, did not al-
ways correlate. Seasonal H1N1-specific MAb TIV-2, which was
not neutralizing at 30 g/ml, mediated CDL at as low as 4
g/ml. MAbs 1009-3E06 and EM-4C04, which were neutraliz-
ing at concentrations similar to those for MAbs 1009-3B06,
1009-3F01, 1009-3B05, and 70-1F02, did not mediate CDL.
Others have reported that stalk-specific neutralizing MAbs
were more cross-reactive than conventional globular head-spe-
cific neutralizing MAbs (1, 2, 13, 20). Therefore, we tested
these three stalk-specific MAbs (all are encoded by the VH1-69
gene [23]) as well as three other MAbs (1009-3B06, TIV-1, and
TIV-2) which showed CDL activity only against target cells
infected with recent seasonal H1N1 virus strains (Table 1 and
Fig. 1) in CDL assays against target cells infected with tempo-
rally distant seasonal H1N1 strains (isolated from 1934 to
2007) (Fig. 2). We found that the three stalk-specific MAbs
lysed target cells infected with all the H1N1 strains tested. In
contrast, the other three MAbs lysed only target cells infected
with recent seasonal H1N1 strains (Fig. 2). One of the three
stalk-specific MAbs (70-1F02) lysed target cells infected with
an H2N1 reassortant virus, X-27 (Fig. 3A). The percent spe-
cific lysis values for MAb 70-1F02 against the H2N1-infected
cells were significantly higher than those for MAb 1009-3B05
at both concentrations tested (Fig. 3B).
Our results showed that most MAbs active in CDL were
neutralizing, but not all neutralizing MAbs can mediate CDL
of target cells. Two of the three stalk-specific neutralizing
MAbs and three of the four conventional globular head-spe-
cific MN/HAI MAbs and one MN/HAI MAb were able
to mediate CDL. Among the MAbs active in CDL, the stalk-
specific MAbs were more cross-reactive than the globular
head-specific MAbs. One potential explanation for the stalk-
specific MAbs being more active in CDL may be the relative
proximity of their binding sites on the HA to the infected cell
membrane (2, 13, 20), on which the activated proteins in the
complement system are deposited, resulting in lysis of the cell
(7). However, we do not know which subclasses the MAbs we
have tested in CDL assays originally belonged to, because we
did not clone the constant regions of the MAbs. About 60% of
human IgG is IgG1, but these MAbs can belong to the IgG3
subclass, a stronger activator of the complement system, or to
the IgG2 or IgG4 subclass, both of which are weaker or are not
activators (8). One of the three stalk-specific MAbs, 70-1F02,
TABLE 1. CDL activities of MAbs against target cells infected with
2009 pandemic or seasonal H1N1 influenza A virus strains
MAb Virus specificitya









1009-3B06 Pandemic and seasonal
H1N1
17.8 15.7
1009-3F01 Pandemic and seasonal
H1N1
14.1 8.6
EM-4C04 Pandemic H1N1 3.4 7.3
TIV-1c Seasonal H1N1 4.6 23.6
MN/HAI (stalk specific)
1009-3B05 Pandemic and seasonal
H1N1 and H5N1d
13.7 43.8
1009-3E06 Pandemic and seasonal
H1N1 and H5N1d
2.1 28.1




TIV-2 Seasonal H1N1 4.9 19.6
MN/HAI
1000-1B02 Pandemic and seasonal
H1N1f
4.8 3.4
1000-2C02 Pandemic and seasonal
H1N1f
5.6 3.7
70-1D02 Pandemic and seasonal
H1N1f
5.3 7.5
70-5C05 Pandemic and seasonal
H1N1f
3.1 2.0
70-5D01 Pandemic and seasonal
H1N1f
0.2 3.1
a Data are from reference 23 except those for MAbs TIV-1 and TIV-2.
b MAbs were tested at 10 g/ml in CDL assays. Low-Tox guinea pig comple-
ment (Cedarlane Laboratories, Burlington, NC) was added at a final dilution of
1:20. Target cells are A549 cells infected with seasonal A/Solomon Islands/3/
2006 (H1N1) or 2009 pandemic A/California/7/2009 (H1N1) influenza A virus
strains at multiplicities of infection of 5 to 10. Percent specific lysis is calculated
as (% lysis by antibody  complement)  (% lysis by complement only)/(%
maximum lysis)  (% lysis by complement only). Maximum lysis was obtained by
lysing target cells by Renex 30 detergent (Uniqema, New Castle, DE). All assays
were performed in triplicate. Positive lysis results are shown in bold.
c Not experimentally determined to bind to the globular head.
d Bound to H5 HA in ELISA.
e Not neutralizing at the highest concentration tested (30 g/ml).
f Bound to 2009 pandemic and seasonal H1 HAs in ELISA.
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was subtype cross-reactive to H2 HA. It is likely that this MAb
recognizes an epitope slightly different from those of other
stalk-specific MAbs or binds to the same epitope at a different
angle.
Recently, Steel et al. reported the generation of new influ-
enza vaccines (a combination of a DNA vaccine and a virus-
like particle) based on the stalk region and their immunoge-
nicity in mice (19). Wei et al. reported induction of stalk-
FIG. 1. CDL activities against target cells infected with seasonal H1N1 and the 2009 pandemic H1N1 strains by seven MAbs at lower antibody
concentrations. MAbs 1009-3B06, 1009-3F01, TIV-1, 1009-3B05, 1009-3E06, 70-1F02, and TIV-2, which had shown moderate to high levels (14 to
44%) of CDL lysis of A/Solomon Islands/3/2006 (H1N1)- and/or A/California/7/2009 (H1N1)-infected A549 target cells (Table 1), were tested
at lower antibody concentrations against target cells infected with the same seasonal H1N1 and 2009 pandemic H1N1 strains. All assays were
performed in triplicate. Averages and standard deviations for three independent experiments are shown.
FIG. 2. Cross-reactivities of MAbs against target cells infected with temporally distant seasonal H1N1 strains. Six MAbs were tested at 4 g/ml
(MAbs 1009-3B06 and TIV-2 were tested at 5 g/ml) against A549 cells infected with recent seasonal strains A/Brisbane/59/2007 (H1N1),
A/Solomon Islands/3/2006 (H1N1), and A/New Caledonia/20/1999 (H1N1) and older strains A/USSR/90/1977 (H1N1) and A/Puerto Rico/8/1934
(H1N1) in CDL assays. Low-Tox guinea pig complement was added at a final dilution of 1:20. All assays were performed in triplicate.
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specific antibodies by a prime/boost combination of plasmid
DNA plus an adenovirus vector or plasmid DNA plus a sea-
sonal vaccine in mice, ferrets, and monkeys (22). Corti et al.
cloned memory B cells producing subtype cross-reactive stalk-
specific IgG from four healthy human donors who received a
seasonal influenza vaccine (1), while Wrammert et al. cloned
human MAbs only from 2009 pandemic influenza virus-in-
fected patients, but not from seasonal influenza vaccine recip-
ients (23). It would be helpful to learn how common these
subtype-cross-reactive stalk-specific antibodies are and about
their biologic functions in vivo.
Although primary infection of BALB/c mice induced CDL
antibodies that were subtype specific (21), human studies con-
ducted after the reemergence of the H1N1 subtype in 1977
found that sera from three young adults, who were unlikely to
have previously experienced H1N1 influenza viruses (they
were exposed to H2N2 and H3N2 subtypes between 1957 and
1976, but not to the H1N1 subtype), showed low levels of CDL
against target cells infected with A/USSR/90/1977 (H1N1)
(16). These low levels of CDL to “novel” influenza virus sub-
types may be mediated by antibodies cross-reactive to H1 and
H2 HAs. A study using mouse MAbs showed that, in addition
to anti-HA antibodies, NA- and nucleoprotein-specific MAbs
mediated CDL of influenza virus-infected target cells, but ma-
trix protein 1-specific MAbs did not (25). Recently Grandea et
al. reported that human MAbs specific to an epitope on the
highly conserved ectodomain of matrix protein 2 (M2) were
able to mediate CDL of CHO cells stably expressing M2 (6).
M2 is known to be expressed abundantly at the cell surface
(10). Therefore, it is also possible that antibodies to NA, nu-
cleoprotein, and M2 may also contribute to CDL subtype
cross-reactivity but probably to a lesser degree.
In conclusion, we have shown that antibodies that bind to
the stalk region of the HA molecule can not only neutralize
free influenza virus particles but can also eliminate virus-
infected cells through CDL. These CDL antibodies are
broadly cross-reactive within an HA subtype, and some ap-
pear to be subtype cross-reactive, suggesting their role in
protection against influenza illness, especially in heterolo-
gous protection.
Nucleotide sequence accession numbers. Variable region
sequences of all MAbs except for TIV-1 and -2 have been
deposited in GenBank under accession numbers HQ689787,
HQ689752, HQ689762, HQ689763, HQ689731, HQ689727,
HQ689750, HQ689751, HQ689789, HQ689761, HQ689778,
HQ689776, HQ689713, HQ689705, HQ689702, HQ689718,
HQ689774, HQ689785, HQ689783, HQ689766, HQ689772,
and HQ689756.
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FIG. 3. Subtype cross-reactivity of MAb 70-1F02 against target cells infected with H1N1 and H2N1 strains. (A) CDL assays were used to test
the stalk-specific MAbs 1009-3B05 (white), 1009-3E06 (light gray), and 70-1F02 (dark gray) against target cells infected with influenza virus strains
A/Solomon Islands/3/2006 (H1N1) and A/Puerto Rico/8/1934 (H1N1) and a reassortant virus, X-27 (H2N1), which has the HA of A/Rockefeller
Institute/5/1957 (H2N2) and the NA of A/NWS/1934 (H1N1). All assays were performed in triplicate. (B) Two MAbs, 1009-3B05 and 70-1F02,
were compared in CDL assays against target cells infected with the A/Solomon Islands/3/2006 (H1N1) virus or the X-27 (H2N1) reassortant virus.
All assays were performed in triplicate. Averages and standard deviations for three independent experiments are shown. The percent specific lysis
values for MAb 70-1F02 were significantly higher against the H2N1-infected cells than those for MAb 1009-3B05 at both 4 and 32 g/ml (P 0.013
and P  0.018, respectively, as determined by Student’s t test, assuming unequal variances).
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